Global challenges in the development and delivery of paediatric antiretrovirals.
Global challenges in the development and delivery of paediatric antiretrovirals.
复制标题
儿科抗逆转录病毒药物的开发和交付面临全球挑战。
DOI：
10.1016/j.drudis.2008.03.018
复制
发表时间：
2008
影响因子：
7.4
通讯作者：
Sohn,AnnetteH
中科院分区：
文献类型：
--
作者：
Bowen,Asha;Palasanthiran,Pamela;Sohn,AnnetteH
到2006年底，与成人28%的覆盖率相比，需要抗逆转录病毒治疗的艾滋病毒儿童中只有15%得到了治疗。提供治疗方面的主要挑战包括缺乏可用于幼儿的儿科抗逆转录病毒药物，以及审查现有抗逆转录病毒制剂安全性和有效性的研究有限。通过使用非专利的固定剂量联合药物，降低了高昂的治疗费用。以证据为基础的管理耐药性战略和扩大中低收入国家儿童药理学试验对儿科抗逆转录病毒药物的成功和未来发展至关重要。
By the end of 2006, compared with 28% coverage for adults, only 15% of children with HIV that needed antiretroviral treatment were receiving it. Major challenges in delivering treatment include the lack of paediatric antiretrovirals that can be dosed in small children and limited studies examining safety and efficacy for existing antiretroviral formulations. The high costs of treatment have been reduced through the use of generic, fixed-dose combination drugs. Evidence-based strategies for managing resistance and the scale-up of pharmacological trials for children in low- and middle-income countries are crucial to the success and future development of paediatric antiretrovirals.